The Effects of Ustekinumab on Health-related Quality of Life in Patients With Moderate to Severe Crohn’s Disease

Autor:	Christopher Gasink, Long-Long Gao, Douglas Jacobstein, Brian G. Feagan, Stephan R. Targan, Bruce E. Sands, C. Han, William J. Sandborn, Philippe Szapary, Yinghua Lang
Rok vydání:	2018
Předmět:	medicine.medical_specialty SF-36 Population Placebo Severity of Illness Index Inflammatory bowel disease Maintenance Chemotherapy 03 medical and health sciences 0302 clinical medicine Crohn Disease Gastrointestinal Agents Maintenance therapy Quality of life Surveys and Questionnaires Internal medicine Severity of illness Ustekinumab medicine Humans 030212 general & internal medicine education education.field_of_study business.industry Gastroenterology Induction Chemotherapy General Medicine medicine.disease humanities Quality of Life 030211 gastroenterology & hepatology business medicine.drug
Zdroj:	Journal of Crohn's and Colitis. 12:883-895
ISSN:	1876-4479 1873-9946
DOI:	10.1093/ecco-jcc/jjy055
Popis:	Background and Aims We assessed the effect of ustekinumab on health-related quality of life [HRQOL] in adults with Crohn's disease [CD]. Methods Patients with moderately to severely active CD and inadequate response or intolerance to tumour necrosis factor antagonists [UNITI-1, n = 741], or conventional therapy [UNITI-2, n = 627] were randomised to placebo, ustekinumab 130 mg, or 6 mg/kg intravenous induction therapy. At Week 8, ustekinumab-treated responders (Crohn's Disease Activity Index [CDAI] reduction ≥100 or CDAI
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad5c0a87af22b73867a5a92028c629a4 https://doi.org/10.1093/ecco-jcc/jjy055 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.